Ken Griffin Bria Cell Therapeutics Corp. Call Options Transaction History

Citadel Advisors LLC

  • $509 Billion
  • Q1 2024

Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2023

Aug 14, 2023
BUY
$5.72 - $7.58 $42,900 - $56,850
7,500 New
7,500 $48,000
Q3 2022

Nov 14, 2022
SELL
$3.0 - $8.31 $274,800 - $761,196
-91,600 Reduced 31.14%
202,600 $1.14 Million

Others Institutions Holding BCTX

# of Institutions
2
Shares Held
13
Call Options Held
0
Put Options Held
0
View Full List

About BriaCell Therapeutics Corp.

BCTX Quotes by TradingView
  • Ticker BCTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,518,000
  • Market Cap $16M
  • Description
  • BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and...
More about BCTX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email